Empagliflozin Is First Diabetes Drug to Hit “Holy Grail” of Cutting Heart Attack, Stroke Deaths in Clinical Trial

The SGLT2 inhibitor empagliflozin, marketed as Jardiance, became the first of the newer diabetes drugs to reduce the risk of heart attacks and stroke deaths in a clinical trial, 1 an achievement that a leading researcher recently said would be the “holy … http://www.ajmc.com/journals/evidence-based-diabetes-management/2015/September-2015/Empagliflozin-Is-First-Diabetes-Drug-to-Hit-Holy-Grail-of-Cutting-Heart-Attack-Stroke-Deaths-in-Clinical-Trial